Claimed effect · Dulaglutide

Does Dulaglutide help with major cardiovascular events?

A
Grade A — established in humans1 large RCT (n=9,901, median 5.4 yr) · effect size: small
Short answerEstablished in humans. 1 large RCT (n=9,901, median 5.4 yr) point the same way: a small effect. Twelve percent fewer heart attacks, strokes and cardiovascular deaths than placebo, in a population where two-thirds had risk factors but no prior cardiovascular disease — the broadest such population of any GLP-1 outcomes trial.

What the studies show

Twelve percent fewer heart attacks, strokes and cardiovascular deaths than placebo, in a population where two-thirds had risk factors but no prior cardiovascular disease — the broadest such population of any GLP-1 outcomes trial.

“During a median follow-up of 5·4 years (IQR 5·1-5·9), the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ratio [HR] 0·88, 95% CI 0·79-0·99; p=0·026).”

Verbatim, from the abstractGerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 2019

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Dulaglutide is a once-weekly GLP-1 receptor agonist made of two GLP-1 analogue chains fused to an antibody fragment, approved for type 2 diabetes since 2014. In the 9,901-person REWIND trial it reduced major cardiovascular events by 12% relative to placebo over 5.4 years in people with diabetes, most of whom had no prior heart disease. It is not approved for weight management and produces modest weight loss — a few kilograms — well below semaglutide or tirzepatide. It is prescription-only everywhere it is sold.

Dulaglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Dulaglutide proven to help with major cardiovascular events?
Yes, as far as human trials can show it: 1 large RCT (n=9,901, median 5.4 yr). LYO grades this outcome A.
What studies are behind the grade?
Twelve percent fewer heart attacks, strokes and cardiovascular deaths than placebo, in a population where two-thirds had risk factors but no prior cardiovascular disease — the broadest such population of any GLP-1 outcomes trial.
Is Dulaglutide approved for this?
Dulaglutide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Dulaglutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →